Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti–interleukin-2 receptor monoclonal antibody basiliximab

Baudouin, Véronique; Crusiaux, Alain; Haddad, Élie; Schandené, Liliane; Goldman, Michel; Loirat, Chantal; Abramowicz, Daniel

doi:10.1097/01.tp.0000073809.65502.8f

Cited by 73 publications

(50 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, most of these therapeutic approaches depend on intravenous application to the recipients and antibodies are often highly immunogenic (19,21). Potent tools to study immunological pathologies such as GvHD in vivo are NOD.Cg-Prkdc scid IL-2rg tm1Wjl /SzJ (NSG) mice, an immunosuppressed strain bearing a mutation in the IL-2 receptor common gamma chain (IL-2Rc) gene (22,23).…”

mentioning

confidence: 99%

Attenuation of graft‐versus‐host‐disease in NOD scid IL‐2Rγ^−/− (NSG) mice by ex vivo modulation of human CD4⁺ T cells

et al. 2016

View full text Add to dashboard Cite

NOD.Cg-Prkdcscid IL-2rg tm1Wjl /SzJ (NSG) mice are a valuable tool for studying Graftversus-Host-Disease (GvHD) induced by human immune cells. We used a model of acute GvHD by transfer of human peripheral blood mononuclear cells (PBMCs) into NSG mice. The severity of GvHD was reflected by weight loss and was associated with engraftment of human cells and the expansion of leukocytes, particularly granulocytes and monocytes. Pre-treatment of PBMCs with the anti-human CD4 antibody MAX.16H5 IgG1 or IgG4 attenuated GvHD. The transplantation of 2 3 10 7 PBMCs without anti-human CD4 pre-treatment induced a severe GvHD (0% survival). In animals receiving 2 3 10 7 PBMCs pre-incubated with MAX.16H5 IgG1 or IgG4, GvHD development was reduced and survival was increased. Immune reconstitution was measured by flow cytometry and confirmed for human leukocytes (CD45), CD3 /CD41 T helper cells. Human B cells (CD19) and monocytes (CD14) could not be detected. Histopathological analysis (TUNEL assay) of the gut of recipient animals showed significantly less apoptotic crypt cells in animals receiving a MAX.16H5 IgG1 pre-incubated graft. These findings indicate that preincubation of an allogeneic graft with an anti-human CD4 antibody may decrease the frequency and severity of GvHD after hematopoietic stem cell transplantation (HSCT) and the need of conventional immunosuppressive drugs. Moreover, this approach most probably provides a safer HSCT that must be confirmed in appropriate clinical trials in the future. V C 2016 International Society for Advancement of Cytometry

show abstract

mentioning

confidence: 99%

Attenuation of graft‐versus‐host‐disease in NOD scid IL‐2Rγ^−/− (NSG) mice by ex vivo modulation of human CD4⁺ T cells

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Une des hypothèses avancées pour expliquer cette différence inter-espèces serait une sécrétion importante de cytokines chez l'homme par rapport au rat et non pas un effet sur la synthèse même de ces cytokines. [18]. Un autre problème lié à l'immunogénicité des anticorps thérapeuti-ques est une augmentation de leur vitesse d'élimination du fait de la formation de complexes immuns rapidement éliminés par le système réticulo-endothélial.…”

Section: Toxicité Liée à L'expression De La Cible Dans Les Tissus Norunclassified

Les complications « toxiques » liées à l’utilisation des anticorps monoclonaux

Pallardy

2009

Med Sci (Paris)

View full text Add to dashboard Cite

Les anticorps monoclonaux (Acm), par définition, permettent une reconnaissance précise et presque exclusive d'une cible. Cet avantage, d'abord exploité dans le domaine du diagnostic, a été étendu à des applications dans le domaine thérapeutique. Au-delà de l'intérêt de la reconnaissance spécifique d'une cible thérapeutique, un des autres intérêts potentiels était une limitation des effets indésirables voire toxiques par opposition aux médicaments « chimiques ». Leur spécificité, alliée au fait que ces produits sont souvent employés dans des pathologies lourdes échappant aux traitements conventionnels, leur confère très souvent un rapport bénéfices/risques élevé. Néanmoins, l'expérience montre que l'utilisation des anticorps monoclonaux en thérapeutique n'est pas dénuée d'effets toxiques chez les patients traités. Les exemples anciens comme le muromonab ou OKT-3 (anti-CD3), ou plus récents comme le TGN1412 (anti-CD28), montrent que la pré-diction des effets potentiellement délétères de ces thérapeutiques ciblées reste complexe. Depuis l'introduction des anticorps monoclonaux dans l'arsenal thérapeutique, l'ensemble des effets toxiques observés en clinique peuvent être regroupés en quatre types : le syndrome de libération de cytokines, l'induction de pathologies auto-immunes, la toxicité d'organes et les infections opportunistes (Tableau I). Il est aussi possible de classer ces effets toxiques en fonction du mécanisme d'action des anticorps utilisés. Dans ce cas, on distingue les effets liés à la cible, comprenant la toxicité en relation avec l'effet pharmacologique ou avec l'expression dans les tissus sains, et les effets non liés à la cible. L'immunogénicité des anticorps, qui est variable en fonction de leur degré d'humanisation, contribue aussi à des effets délétères comme la formation de complexes immuns ou l'altération des caracté-ristiques pharmacocinétiques (➜). Toxicité liée à la cibleToxicité en relation avec l'effet pharmacologique Certaines des toxicités observées sont reliées directement aux effets pharmacologiques des anticorps sur la > L'expérience clinique montre que l'utilisation des anticorps monoclonaux n'est pas dénuée d'effets toxiques chez les patients traités. Les exemples anciens comme le muromonab ou OKT-3 (anti-CD3), ou plus récents comme le TGN1412 (anti-CD28) montrent que la prédiction des effets potentiellement délétères de ces thérapeutiques ciblées reste complexe. L'ensemble des effets toxiques observés en clinique peut être classifié en quatre types : le syndrome de libération de cytokines, l'induction de pathologies auto-immunes, la toxicité d'organe et les infections opportunistes. L'immunogénicité des anticorps, qui est variable en fonction de leur degré d'humanisation, contribue aussi à des effets délétères sous la forme par exemple de complexes immuns. L'accident récent observé avec le TGN1412 montre bien que la relative confiance en termes de sécurité d'emploi liée à l'utilisation des anticorps en thérapeutique n'est plus d'actualité et révèle aussi les limites des modèles non...

show abstract

“…Patients can develop hypotension, tachycardia, cardiac failure, bronchospasm, pulmonary edema, respiratory failure, urticaria, rash, pruritis, and sneezing. [271][272][273] Antichimeric IgE antibodies appear to be responsible for anaphylaxis following retreatment with the medication. 272 The IgE antibodies, however, do not recognize daclizumab, a similar genetically engineered murine monoclonal antibody that binds the IL-2 receptor.…”

Section: Il-2 Receptor Antagonistsmentioning

confidence: 99%

“…[271][272][273] Antichimeric IgE antibodies appear to be responsible for anaphylaxis following retreatment with the medication. 272 The IgE antibodies, however, do not recognize daclizumab, a similar genetically engineered murine monoclonal antibody that binds the IL-2 receptor. 273 Common adverse events associated with basiliximab include abdominal pain, vomiting, dizziness, insomnia, edema, hypertension, anemia, dysuria, cough, dyspnea, candidiasis, CMV infection, and fever.…”

Section: Il-2 Receptor Antagonistsmentioning

confidence: 99%

“…307 A detailed description of these reactions involving basiliximab has been published and involves renal transplant patients with early graft loss and is more prevalent on repeat exposure or in patients in whom concomitant immunosuppression was discontinued. [271][272][273] Recommendations for the monitoring of IL-2 receptor antagonists in patients with lung disease and lung transplant recipients: linked to birth defects in the Danish Birth Registry cohort study 345 and to growth retardation in humans 346 and in rats. 347 Although azathioprine crosses the placenta in humans, concentrations in the fetus are very low.…”

Section: Daclizumabmentioning

confidence: 99%

See 1 more Smart Citation

Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients

Baughman

Meyer

Nathanson

et al. 2012

Chest

View full text Add to dashboard Cite

Objectives: Immunosuppressive pharmacologic agents prescribed to patients with diffuse interstitial and infl ammatory lung disease and lung transplant recipients are associated with potential risks for adverse reactions. Strategies for minimizing such risks include administering these drugs according to established, safe protocols; monitoring to detect manifestations of toxicity; and patient education. Hence, an evidence-based guideline for physicians can improve safety and optimize the likelihood of a successful outcome. To maximize the likelihood that these agents will be used safely, the American College of Chest Physicians established a committee to examine the clinical evidence for the administration and monitoring of immunosuppressive drugs (with the exception of corticosteroids) to identify associated toxicities associated with each drug and appropriate protocols for monitoring these agents. Methods: Committee members developed and refi ned a series of questions about toxicities of immunosuppressives and current approaches to administration and monitoring. A systematic review was carried out by the American College of Chest Physicians. Committee members were supplied with this information and created this evidence-based guideline. Conclusions: It is hoped that these guidelines will improve patient safety when immunosuppressive drugs are given to lung transplant recipients and to patients with diffuse interstitial lung disease. CHEST 2012; 142(5):e1S-e111SAbbreviations: ACCP 5 American College of Chest Physicians; ALT 5 alanine aminotransferase; ATG 5 antithymocyte globulin; CHF 5 congestive heart failure; CMV 5 cytomegalovirus; CNI 5 calcineurin inhibitor; COI 5 confl ict of interest; CsA 5 cyclosporin A; FDA 5 US Food and Drug Administration; HBV 5 hepatitis B virus; HMG-CoA 5 b -hydroxy-bmethylglutaryl-coenzyme A; HSP 5 Health and Science Policy Committee; IL2RA 5 IL-2 receptor a ; ILD 5 interstitial lung disease; IPF 5 idiopathic pulmonary fi brosis; ITP 5 idiopathic thrombocytopenia purpura; LAM 5 lymphangioleiomyomatosis; MESNA 5 sodium 2-sulfonylethanesufonate; MPA 5 mycophenolic acid; mTOR 5 mammalian target of rapamycin; PTLD 5 posttransplant lymphoproliferative disease; RCT 5 randomized controlled trial; SIRS 5 systemic infl ammatory response syndrome; TNF 5 tumor necrosis factor; TPMT 5 thiopurine methyltransferase

show abstract

Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti–interleukin-2 receptor monoclonal antibody basiliximab

Abstract: Patients exposed to chimeric antibodies may develop an anti-idiotypic IgE response that can trigger anaphylactic shock on further exposure. Specific anti-idiotypic IgE may be bound to basophils even in the absence of circulating IgE.

Cited by 73 publications

References 13 publications

Attenuation of graft‐versus‐host‐disease in NOD scid IL‐2Rγ^−/− (NSG) mice by ex vivo modulation of human CD4⁺ T cells

Attenuation of graft‐versus‐host‐disease in NOD scid IL‐2Rγ^−/− (NSG) mice by ex vivo modulation of human CD4⁺ T cells

Les complications « toxiques » liées à l’utilisation des anticorps monoclonaux

Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients

Contact Info

Product

Resources

About

Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti–interleukin-2 receptor monoclonal antibody basiliximab

Abstract: Patients exposed to chimeric antibodies may develop an anti-idiotypic IgE response that can trigger anaphylactic shock on further exposure. Specific anti-idiotypic IgE may be bound to basophils even in the absence of circulating IgE.

Cited by 73 publications

References 13 publications

Attenuation of graft‐versus‐host‐disease in NOD scid IL‐2Rγ−/− (NSG) mice by ex vivo modulation of human CD4+ T cells

Attenuation of graft‐versus‐host‐disease in NOD scid IL‐2Rγ−/− (NSG) mice by ex vivo modulation of human CD4+ T cells

Les complications « toxiques » liées à l’utilisation des anticorps monoclonaux

Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients

Contact Info

Product

Resources

About

Attenuation of graft‐versus‐host‐disease in NOD scid IL‐2Rγ^−/− (NSG) mice by ex vivo modulation of human CD4⁺ T cells

Attenuation of graft‐versus‐host‐disease in NOD scid IL‐2Rγ^−/− (NSG) mice by ex vivo modulation of human CD4⁺ T cells